Single-Dose Tafenoquine to Prevent Relapse of <i>Plasmodium vivax</i> Malaria

2019282 citationsJournal Articlebronze Open Access

Authors

Marcus Lacerda · Fundação Oswaldo Cruz

Alejandro Llanos‐Cuentas · Universidad Peruana Cayetano Heredia

Srivicha Krudsood · Mahidol University

Chanthap Lon · Armed Forces Research Institute of Medical Science

David Saunders · Armed Forces Research Institute of Medical Science

Rezika Mohammed · University of Gondar

Daniel Yilma

Abstract

Single-dose tafenoquine resulted in a significantly lower risk of P. vivax recurrence than placebo in patients with phenotypically normal G6PD activity. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; DETECTIVE ClinicalTrials.gov number, NCT01376167 .).

Topics & Keywords

Synthesis and bioactivity of alkaloids Venomous Animal Envenomation and Studies Neonatal Health and Biochemistry

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 3, pp. 215-228

DOI: 10.1056/nejmoa1710775

Field-Weighted Citation Impact: 14.55